Please enable JavaScript.
Coggle requires JavaScript to display documents.
malignant brain tumors - Coggle Diagram
malignant brain tumors
What genetic and molecular changes drive the growth and progression of malignant brain tumors such as glioblastomas and medulloblastomas? How can these be targeted for therapy?
Mutations in genes like IDH1/2 produce oncometabolite 2-hydroxyglutarate (2HG), promoting malignant transformation and altered metabolism in tumor cells.
Other key genetic alterations include TP53, EGFR amplification, and alterations in signaling pathways affecting cell proliferation and survival.
Targeting these molecular changes includes mutant IDH inhibitors (e.g., ivosidenib, vorasidenib) that reduce 2HG production and tumor growth. These show promise especially in IDH-mutant gliomas.
How can the blood-brain barrier be effectively breached or bypassed to deliver therapeutic agents directly to dispersed tumor cells?
Strategies include developing drugs with enhanced BBB penetration, such as brain-penetrant IDH inhibitors.
Alternative methods involve focused ultrasound to temporarily disrupt the BBB, nanoparticles, convection-enhanced delivery, and implantable wafers delivering chemotherapy directly to tumor sites.
What roles do tumor genetics (e.g., IDH gene mutations) and gene expression profiles play in predicting tumor response to therapies like radiation, chemotherapy, and immunotherapy?
IDH-mutant gliomas generally respond better to radiation and chemotherapy and have a more favorable prognosis than IDH-wild-type tumors.
Metabolic biomarkers like 2HG can be monitored via magnetic resonance spectroscopy (MRS) to gauge treatment response.
Gene expression profiles can guide personalized therapy and help predict which patients might respond to immunotherapy or targeted agents.
How can diagnostic tools such as liquid biopsy and AI-based imaging analysis be optimized for early detection, treatment monitoring, and prognosis prediction?
Liquid biopsy analyzing circulating tumor DNA (ctDNA) and metabolites like 2HG enables minimally invasive monitoring of tumor dynamics.
Artificial intelligence applied to MRI and other imaging modalities improves early tumor detection, delineation, and response evaluation.
Combining molecular diagnostics with advanced imaging supports better prognosis prediction and personalized treatment planning.
What combination of treatments—including targeted drugs, immunotherapies, oncolytic viruses, and radiation protocols—can yield the best outcomes for patients with malignant brain tumors?
-
-
Emerging treatments include immunotherapies (e.g., immune checkpoint inhibitors), oncolytic viruses, and novel radiosensitizers used in combinatory regimens to improve outcomes.
How does tumor biology differ between patient groups (e.g., by sex or age), and how can this knowledge inform personalized treatment plans?
Tumor genetics and biology can vary by age, sex, and tumor subtype influencing disease course and response.
-
Tailoring therapies to patient-specific tumor molecular profiles and demographic factors is a current precision oncology focus
How can quality of life and symptom management be integrated into clinical trials and treatment approaches to benefit patients with malignant brain tumors?
Symptom control including neurological deficits, seizures, and cognitive effects are managed alongside tumor treatment.
-
Supportive therapies and multidisciplinary care models aim to improve overall well-being during and after treatment.